Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Apr 30;33(6):E81–E86. doi: 10.1002/clc.20719

Mechanism and Clinical Significance of the Prothrombotic State in Patients With Essential Hypertension

Ping Yang 1,, Ya‐Fen Liu 2, Li Yang 1, Qun Wei 1, Hong Zeng 1
PMCID: PMC6653447  PMID: 20552613

Abstract

Background

Thrombotic, rather than hemorrhagic, events represent a major complication of hypertension. This study aims to explore the mechanism of the hypercoagulative state in hypertension and to assess its clinical significance.

Hypothesis

The hypercoagulative state and even the prothrombotic state exists in patients with hypertension. This may be attributed to an impairment of the endothelium.

Methods

A total of 81 patients suffering from essential hypertension were classified into 3 groups (grade 1: n = 27; grade 2: n = 36; grade 3: n = 18) and an additional 28 nonhypertensive patients were used as the control group. This study determined the changes of platelet activation marker P‐selectin (CD62P), plasma fibrinogen, plasminogen activitor inhibitor‐1 (PAI‐1), and endothelium function.

Results

The percentage of CD62P+ platelets and the concentration of plasma fibrinogen and PAI‐1 in the hypertension group was significantly higher than those in the control group. These increments coincided with the elevation of blood pressure. A significant difference was found between any of the 2 hypertension subgroups in the percentages of CD62P+ platelets (P < 0.001) and the concentration of PAI‐I (P < 0.05). No difference was noted between the hypertension grade 1 and 2 groups in the concentration of plasma fibrinogen (P = 0.079); however, a significant difference was found between any of the other 2 subgroups (P < 0.001). Flow‐mediated dilation (FMD) in the hypertension group was significantly lower than that in the control group.

Conclusions

The hypercoagulative state exists in patients with hypertension and this state was more obvious with the elevation of blood pressure and coincided with an impairment in the degree of endothelium‐dependent vasodilation. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (401.2 KB).

References

  • 1. Lip GY. Hypertension and the prothrombotic state. J Hum Hypertens 2000; 14(10–11): 687–690. [DOI] [PubMed] [Google Scholar]
  • 2. Dielis AW, Smid M, Spronk HM, et al. The prothrombotic paradox of hypertension: role of the renin‐angiotensin and kallikrein‐kinin systems. Hypertension 2005; 46(6): 1236–1242. [DOI] [PubMed] [Google Scholar]
  • 3. Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 2000; 101(3): 218–220. [DOI] [PubMed] [Google Scholar]
  • 4. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007; 49(3): 432–438 Epub 2007; 22. [DOI] [PubMed] [Google Scholar]
  • 5. Huisse MG, Lanoy E, Tcheche D, et al. Prothrombotic markers and early spontaneous recanalization in ST‐segment elevation myocardial infarction. Thromb Haemost 2007; 98(2): 420–426. [PMC free article] [PubMed] [Google Scholar]
  • 6. Zhang X, Hu Y, Hong M, et al. Plasma thrombomodulin, fibrinogen, and activity of tissue factor as risk factors for acute cerebral infarction. Am J Clin Pathol 2007; 128(2): 287–292. [DOI] [PubMed] [Google Scholar]
  • 7. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006; 19(12): 1293–1299. [DOI] [PubMed] [Google Scholar]
  • 8. Celermajer DS, Sorensen KE, Gooch VM, et al. Non‐invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–1115. [DOI] [PubMed] [Google Scholar]
  • 9. Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag 2008; 4(1): 89–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. da Costa Martins P, García‐Vallejo JJ, van Thienen JV, et al. P‐selectin glycoprotein ligand‐1 is expressed on endothelial cells and mediates monocyte adhesion to activated endothelium. Arterioscler Thromb Vasc Biol 2007; 27(5): 1023–1029. [DOI] [PubMed] [Google Scholar]
  • 11. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow‐mediated dilatation: implications for the assessment of endothelial function. J Physiol 2005; 568: 357–369. Epub 2005; 28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Moll Cell Cardiol 1999; 31(1): 51–60. [DOI] [PubMed] [Google Scholar]
  • 13. Khalil A, Sareen R, Mallika V, et al. Non‐invasive evaluation of endothelial function, arterial mechanics and nitric oxide levels in children of hypertensive parents. Indian Heart J 2008; 60(1): 34–38. [PubMed] [Google Scholar]
  • 14. Raij L. Nitric oxide in the pathogenesis of cardiac disease. J Clin Hypertens (Greenwich) 2006; 8(12):4 30–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Wiel E, Vallet B, Cate H. The endothelium in intensive care. Crit Care Clin 2005; 21(3): 403–416. [DOI] [PubMed] [Google Scholar]
  • 16. Lip GY. Hypertension, platelets, and the endothelium: the “thrombotic paradox” of hypertension (or “Birmingham paradox”) revisited. Hypertension 2003; 41(2): 199–200. [DOI] [PubMed] [Google Scholar]
  • 17. Tomiyama H, Kimura Y, Mitsuhashi H, et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 1998; 31(1 pt 2): 321–327. [DOI] [PubMed] [Google Scholar]
  • 18. Brodsky SV, Malinowski K, Golightly M, et al. Plasminogen activator inhibitor‐1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 2002; 106(18): 2372–2378. [DOI] [PubMed] [Google Scholar]
  • 19. Remkov A, Remko M. The role of renin‐angiotensin system in prothrombotic state in essential hypertension. Physiol Res 2009; Feb 27. [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  • 20. Nishimura H, Tsuji H, Masuda H, et al. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb Haemost 1999; 82(5): 1516–1521. [PubMed] [Google Scholar]
  • 21. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin‐angiotensin system on plasma PAI‐1. Hypertension 1998; 32(6): 965–971. [DOI] [PubMed] [Google Scholar]
  • 22. Diamantopoulos EJ, Andreadis EA, Vassilopoulos CV, et al. Increased plasma plasminogen activator inhibitor‐1 levels: a possible marker of hypertensive target organ damage. Clin Exp Hypertens 2003; 25(1): 1–9. [DOI] [PubMed] [Google Scholar]
  • 23. Chertin B, Solari V, Reen DJ, et al. Up‐regulation of angiotensin‐converting enzyme (ACE) gene expression induces tubulointerstitial injury in reflux nephropathy. Pediatr Surg Int 2002; 18(7): 635–639. Epub 2002; 25. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES